Booster Therapeutics’ small molecules activate the 20S proteasome, a component of cells that gets rid of misfolded proteins. Parkinson’s and Alzheimer’s are potential disease targets for the startup, which launched with $15 million in seed financing.
The post Startup Booster Therapeutics Launches to Usher In Next Wave of Protein-Degrading Drugs appeared first on MedCity News.
